Power of gradients.

Area of Science:

• Cardiovascular Medicine
• Interventional Cardiology
• Valvular Heart Disease

Background:

• Severe symptomatic aortic stenosis (SSAS) poses significant mortality risks.
• Transcatheter aortic valve replacement (TAVR) is a primary treatment for SSAS.
• Patient selection for TAVR requires careful consideration of hemodynamic parameters.

Discussion:

• Baseline gradient is a critical predictor of TAVR outcomes in SSAS.
• Higher mean gradients correlate with reduced mortality post-TAVR.
• The benefit of TAVR in low-gradient SSAS remains variable and requires further investigation.

Key Insights:

• Patients with high baseline transaortic gradients demonstrate superior survival post-TAVR.
• Each 10 mm Hg increase in mean gradient is associated with a 20% reduction in mortality.
• Low-gradient severe aortic stenosis presents a complex clinical scenario with uncertain TAVR benefits.

Outlook:

• Further research is needed to optimize TAVR selection criteria for low-gradient SSAS patients.
• Investigating alternative therapeutic strategies for low-gradient SSAS is warranted.
• Long-term outcome data will refine risk stratification and treatment guidelines for TAVR.